Applications of Nanoparticles in Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".

Deadline for manuscript submissions: closed (28 February 2026) | Viewed by 1094

Special Issue Editors


E-Mail Website
Guest Editor
School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
Interests: immunology; nanoparticles; vaccines; adjuvants

E-Mail Website
Guest Editor
School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
Interests: immunology; nanoparticles; vaccines; cancer; ageing

E-Mail Website
Guest Editor
School of Science, RMIT University, Melbourne, Australia
Interests: drug delivery; nanoparticles; gene therapy

Special Issue Information

Dear Colleagues,

Nanoparticles have been extensively researched over the last several decades for their potential in vaccine applications. They can be utilized as a delivery system or carrier, and some even have their own self-adjuvating properties. The application of nanoparticles in vaccines is also very topical, given the recent spotlight on lipid nanoparticles for the delivery of mRNA vaccines for COVID-19. There are numerous nanoparticle types, with properties including material composition, shape, size, surface functionalization, and antigen incorporation techniques affecting how vaccines are recognized, their cellular association, and antigen delivery. Identifying the type of immune response elicited by nanoparticle-based vaccines and their mechanism of action is also important in optimal vaccine design. The multitude of nanoparticles available and their malleable properties make them ideal for vaccine applications for current and emerging infectious diseases and novel vaccines for cancer.

We are pleased to invite you to contribute to this Special Issue, which will showcase a collection of scientific papers on applications of nanoparticles in vaccines. Research areas may include (but are not limited to) nanoparticle-based vaccine development, antigen incorporation and vaccine design, modes of action, immune reactivity, applications and disease models and translation, including clinical trials. Original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Kirsty Wilson
Prof. Dr. Magdalena Plebanski
Dr. Nhiem L. Tran
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • vaccine design
  • nanoparticle applications in vaccines
  • antigen incorporation with nanoparticles
  • physicochemical properties of nanoparticles
  • adjuvant properties of nanoparticles
  • mechanisms of nanovaccines
  • immune response
  • disease models

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 3964 KB  
Article
Biosynthesis and Immunological Evaluation of a Dual-Antigen Nanoconjugate Vaccine Targeting Group A Streptococcus
by Xiaoxia Li, Xiang Wang, Decong Kong, Hua Jiang, Ying Chen, Wenhua Huang and Yongqiang Jiang
Vaccines 2026, 14(3), 237; https://doi.org/10.3390/vaccines14030237 - 4 Mar 2026
Cited by 1 | Viewed by 714
Abstract
Background: Group A Streptococcus (GAS) induces a wide spectrum of human diseases, ranging from superficial infections to life-threatening invasive conditions and post-infectious sequelae such as rheumatic heart disease, posing a heavy global health burden. Critically, there is still no licensed commercial vaccine [...] Read more.
Background: Group A Streptococcus (GAS) induces a wide spectrum of human diseases, ranging from superficial infections to life-threatening invasive conditions and post-infectious sequelae such as rheumatic heart disease, posing a heavy global health burden. Critically, there is still no licensed commercial vaccine against GAS, making the development of novel, effective vaccines against this pathogen an urgent and crucial unmet medical need. Methods: We developed a dual-antigen nanoconjugate vaccine against GAS. The Group A Carbohydrate polyrhamnose backbone (GACPR) and truncated SLO were site-specifically conjugated via Protein Glycan Coupling Technology (PGCT) in engineered E. coli, and then linked to ferritin nanoparticles using the SnoopTag/SnoopCatcher system. Safety, immunogenicity, and protective efficacy were evaluated in murine models. Results: The nanovaccine was successfully synthesized with high purity. It elicited robust GAC- and SLO-specific IgG/IgG1 responses, conferred 90% survival against lethal GAS challenge (vs. 0–50% in controls), reduced bacterial loads in organs, and lowered inflammatory cytokines. Passive immunization with vaccine-induced serum also achieved 90% survival. No abnormal biochemical indicators, inflammatory responses, or organ pathology were observed. Conclusions: This study successfully developed a bivalent nanoparticle vaccine against GAS. This novel nanovaccine exhibits excellent safety, strong immunogenicity, and effective protection against GAS, providing a promising vaccine candidate. Full article
(This article belongs to the Special Issue Applications of Nanoparticles in Vaccines)
Show Figures

Figure 1

Back to TopTop